UNSPSC 51291508: Efetozole

This classification denotes an antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MPI4B0COZ7. European Medicines Agency schedules Efetozole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06466MIG. Efetozole generally arises in the molecular formula C12H14N2.

The term EFETOZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 2, no. 3, 1988, list 28.) EFETOZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule efetozole under HS 29332990 and SITC 51573. As of Q4 2014, EFETOZOLE remains the US FDA Preferred Term for this commodity. Efetozole bears US NLM identifiers UMLS ID C2348381 and NCI Concept Code C72750. SMILES: CC1=NC=CN1C(C)C2=CC=CC=C2.

UNSPSC 51291508 Efetozole is a Commodity code that in practice covers pharmaceutical products and related health-supply procurement by state and local agencies, though recent solicitations show limited direct activity under the efetozole designation itself. State and local governments soliciting under this code are acquiring naloxone, generic pharmaceuticals, over-the-counter products, and drug deactivation systems through competitive bidding and cooperative purchasing arrangements. The issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances such as the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), which aggregates demand across member states and local jurisdictions.

Recent activity shows geographic spread across Florida, Texas, and Minnesota, with MMCAP's procurement reaching participating jurisdictions in Oregon as well. The Seminole County, Florida IFB60459723LAS (posted June 30, 2026, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, requiring E-Verify compliance and insurance coverage including workers' compensation and commercial general liability. The Texas Health and Human Services Commission issued RFI HHS0017013 (April 3, 2026) to explore direct-to-manufacturer prescription programs and vendor capabilities for therapeutic pharmacy initiatives operating outside traditional pharmacy benefit manager and group purchasing organization channels. MMCAP's S1070000015802 RFP (posted January 20, 2026, due March 26, 2026) established multiple contracts for generic pharmaceuticals and OTC products with three authorized wholesalers, requiring vendors to maintain specific insurance limits including $5,000,000 commercial general liability per occurrence and comply with current Good Manufacturing Practices and the Drug Supply Chain Security Act, with awards effective July 1, 2026.